Skip to main content

Coronavirus (COVID-19): Visitor Restrictions, Resources, and Updates

Explore URMC
menu

Deborah Mulford, M.D.

Publications

Showing all 13 journal articles & 1 books available

Journal Articles

10/2014
Advani AS, McDonough S, Copelan E, Willman C, Mulford DA, List AF, Sekeres MA, Othus M, Appelbaum FR. "SWOG0919: a Phase 2 study of idarubicin and cytarabine in combination with pravastatin for relapsed acute myeloid leukaemia." British journal of haematology.. 2014 Oct 0; 167(2):233-7. Epub 2014 Jul 18.

12/2013
Liesveld JL, O'Dwyer K, Walker A, Becker MW, Ifthikharuddin JJ, Mulford D, Chen R, Bechelli J, Rosell K, Minhajuddin M, Jordan CT, Phillips GL. "A phase I study of decitabine and rapamycin in relapsed/refractory AML." Leukemia research.. 2013 Dec 0; 37(12):1622-7. Epub 2013 Sep 08.

4/30/2012
Raza A, Galili N, Mulford D, Smith SE, Brown GL, Steensma DP, Lyons RM, Boccia R, Sekeres MA, Garcia-Manero G, Mesa RA. "Phase 1 dose-ranging study of ezatiostat hydrochloride in combination with lenalidomide in patients with non-deletion (5q) low to intermediate-1 risk myelodysplastic syndrome (MDS)." Journal of hematology & oncology. 2012 Apr 30; 5:18. Epub 2012 Apr 30.

4/15/2012
Raza A, Galili N, Smith SE, Godwin J, Boccia RV, Myint H, Mahadevan D, Mulford D, Rarick M, Brown GL, Schaar D, Faderl S, Komrokji RS, List AF, Sekeres M. "A phase 2 randomized multicenter study of 2 extended dosing schedules of oral ezatiostat in low to intermediate-1 risk myelodysplastic syndrome." Cancer.. 2012 Apr 15; 118(8):2138-47. Epub 2011 Sep 01.

8/2011
Liesveld JL, Rosell KE, Bechelli J, Lu C, Messina P, Mulford D, Ifthikharuddin JJ, Jordan CT, Phillips Ii GL. "Proteasome inhibition in myelodysplastic syndromes and acute myelogenous leukemia cell lines." Cancer investigation.. 2011 Aug 0; 29(7):439-50.

7/21/2011
Sekeres MA, Gundacker H, Lancet J, Advani A, Petersdorf S, Liesveld J, Mulford D, Norwood T, Willman CL, Appelbaum FR, List AF. "A phase 2 study of lenalidomide monotherapy in patients with deletion 5q acute myeloid leukemia: Southwest Oncology Group Study S0605." Blood.. 2011 Jul 21; 118(3):523-8. Epub 2011 May 06.

11/1/2010
Rosenblat TL, McDevitt MR, Mulford DA, Pandit-Taskar N, Divgi CR, Panageas KS, Heaney ML, Chanel S, Morgenstern A, Sgouros G, Larson SM, Scheinberg DA, Jurcic JG. "Sequential cytarabine and alpha-particle immunotherapy with bismuth-213-lintuzumab (HuM195) for acute myeloid leukemia." Clinical cancer research : an official journal of the American Association for Cancer Research.. 2010 Nov 1; 16(21):5303-11. Epub 2010 Sep 21.

12/2008
Walker AR, Komrokji RS, Ifthikharuddin J, Messina P, Mulford D, Becker M, Friedberg J, Oliva J, Phillips G, Liesveld JL, Abboud C. "Phase I study of cladribine, cytarabine (Ara-C), granulocyte colony stimulating factor (G-CSF) (CLAG Regimen) and simultaneous escalating doses of imatinib mesylate (Gleevec) in relapsed/refractory AML." Leukemia research.. 2008 Dec 0; 32(12):1830-6. Epub 2008 Jun 20.

7/2008
Laughlin TS, Becker MW, Liesveld JL, Mulford DA, Abboud CN, Brown P, Rothberg PG. "Rapid method for detection of mutations in the nucleophosmin gene in acute myeloid leukemia." The Journal of molecular diagnostics : JMD.. 2008 Jul 0; 10(4):338-45. Epub 2008 Jun 13.

2004
Mulford, D.; Pandit-Taskar, N.; McDevitt, M.; Finn, R.; Weiss, M.; Apostolidis, C.; Morgenstern, A.; Divgi, C.; Larson, S.; Scheinberg, D., Jurcic, J.;. "Sequential therapy with cytarabine and bismuth-213 (213Bi)-labeled-HuM195 (anti-CD33) for acute myeloid leukemia (AML)". Blood. 2004; .

2003
Mulford, D.; Maslak, P.; Weiss, M.; Scheinberg, D.; Jurcic, J.;. "Reducing standard postremission chemotherapy in acute promyelocytic leukemia (APL) with risk-adapted therapy." Blood. 2003; : 619a.

Landau, H.; Mulford, D.; Jurcic, J.; Lammanna, N.; Weiss, M. "Retrospective study to determine if the presence of trisomy 12 by FISH and cytogenetics is predictive of a slowly-progressive chronic lymphocytic leukemia." .

Gajra A; Karim NA; Mulford DA; Villaruz LC; Matrana MR; Haythem YA; Santos ES; Berry T; Ong TJ; Sanford A; Amiri K; Spigel DR. "nab-Paclitaxel-Based Regimens in Underserved Patient Populations Part 2: The ABOUND.PS2 Study in Patients with NSCLC and a Performance Status of 2." Frontiers in Oncology, section Thoracic Oncology. .

Books & Chapters

2006
Chapter Title: Monoclonal Antibody Therapies of Cancer
Book Title: Cancer Chemotherapy and Biotherapy
Author List: Scheinberg DA, Mulford DA, Jurcic JG, Junghans RP, Sgouros G.
Published By: Baltimore: Lippincott, Williams, And Wilkins2006